On April 15, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. announced that the FDA will convene a Pharmacy Compounding Advisory Committee meeting in July 2026 to review whether roughly a dozen peptide substances should be moved onto the 503A Bulks List — the register of drug ingredients compounding pharmacies are allowed to prepare on an individual-prescription basis. The announcement triggered an immediate market reaction: Hims & Hers Health (NYSE: HIMS) closed April 16 at $26.98, up 11.07% on volume of 74.6 million shares (111% above three-month average), after climbing another 6.88% premarket. Over two trading days the stock rose 25% — a meaningful recovery after the company's mid-2025 compounded-GLP-1 setback.

Why It Matters

The peptide review lands directly in the male-sexual-health and longevity-wellness markets that Hims has been building out. PT-141 is a next-generation sexual-desire drug already available through some telehealth platforms as a compounded product; if it clears the 503A list, it becomes broadly prescribable and Hims' existing subscriber base (millions of ED and hair-loss patients) is the obvious distribution channel. It's also a political pivot: after 2025's FDA enforcement against compounded tirzepatide cratered Hims' stock, the Kennedy HHS has chosen to broaden rather than narrow compounding access — a policy posture that directly benefits sexual-health telehealth if sustained.

The 503A reclassification matters because peptides in FDA "Category 2" restricted status can't be compounded for patients; moving them to the bulks list would open the door to personalized-dose preparations by licensed compounding pharmacies. Twelve peptides are in the initial tranche; seven additional peptides are queued for a follow-up review. Kennedy's announcement, foreshadowed on his Joe Rogan appearance in late March, signals the first substantive reversal of 2023 FDA restrictions that effectively cleared peptide shelves.

For Hims & Hers specifically, the policy shift is doubly relevant. The company acquired a California peptide manufacturing facility in early 2025, giving it direct capacity to compound GLP-1 alternatives and sexual-health-adjacent peptides (PT-141/bremelanotide, which markets to sexual arousal; BPC-157 for recovery; CJC-1295/Ipamorelin for growth hormone axis). A Bank of America analyst raised the HIMS price target from $21 to $25 citing the dual opportunity: converting GLP-1 compounding capacity to peptide production and a broader catalog of personalized peptide therapies for the telehealth platform.

The broader telehealth-compounding ecosystem — including Ro, Lemonaid, Eden, and peptide-focused upstarts — also benefits. Compounding pharmacies that maintained peptide practices in regulatory gray zones can now plan for a clearer legal footing by July. The advisory committee meeting won't guarantee approval; 503A Bulks List additions require a positive committee recommendation followed by FDA rulemaking. But the signaling alone has reshaped trading in the sector.

Sources

Update — 2026-04-19

Initial entry — story first created.

Update — 2026-05-01

The first major scientific opposition to the planned peptide reset arrived on April 29, 2026, when STAT News published a high-profile First Opinion essay by Stanford stem-cell researcher Paul Knoepfler arguing that Kennedy is "working to undo" the 2023 FDA Category 2 restrictions on peptides like BPC-157 and GHK-Cu "with major risks to the public." The essay specifically calls out the lack of randomized clinical-trial data behind the popular wellness-clinic peptides and warns that the 503A Bulks List path would expose patients to compounded preparations whose safety profile FDA rejected on evidence grounds three years ago.

The op-ed marks the first concentrated push-back from mainstream biomedical-research voices ahead of the FDA Pharmacy Compounding Advisory Committee meeting planned for July 2026. For Hims & Hers — whose stock has held most of the post-April 16 gain heading into its May 11 Q1 earnings call — the Knoepfler critique is the first credible counter-narrative that institutional investors will be reading into the trade. The company's Q1 2026 revenue guidance is $600–$625M (versus $654M consensus), reflecting the GLP-1 transition headwind; whether the peptide pipeline is treated as upside catalyst or regulatory risk through the rest of 2026 will hinge significantly on whether the July advisory committee follows the STAT-aligned scientific consensus or the HHS political signal.

New Sources

Update — 2026-07-03

As the July FDA Pharmacy Compounding Advisory Committee meeting approaches, the peptide reset hit its first hard institutional wall — from inside the agency. In review documents released the week of June 29, 2026, the FDA's own scientific reviewers recommended against adding seven of the popular peptides to the 503A Bulks List, citing thin evidence of benefit and unresolved safety risks. Reuters, Endpoints News, MedPage Today, and NBC News all reported that agency staff found "little evidence of benefit" for the compounds — including doping-flagged substances BPC-157 and TB-500 — undercutting the case Secretary Kennedy's HHS has been building. Notably, most of the injectable peptides sold in the U.S. today are produced by compounding pharmacies operating in a regulatory gray zone.

Separately, reporting from PBS NewsHour, STAT, and Healio revealed the advisory panel itself has been stacked with longevity- and wellness-oriented physicians who promote the very chemicals under review, drawing conflict-of-interest criticism ahead of the vote. For the sexual-health angle, the stakes remain concentrated in PT-141/bremelanotide (marketed for sexual desire) and the broader men's-wellness peptide catalog that telehealth players like Hims & Hers have been positioning to compound at scale. A negative committee recommendation in July would blunt that opportunity; the split between FDA's career scientists and its politically appointed panel makes the outcome genuinely uncertain.

New Sources